PDGFRB and hepatocellular carcinoma: In contrast, sorafenib8, a clinically used drug for treating HCC and is a multi-kinase inhibitor targeting Raf kinases, VEGFR and platelet derived growth factor receptor (PDGFR), reduced average network formation by 30.7% when 8 μM of the drug was used for two days (Supplementary Table S2).